Total Payments
$361,039
2024 Payments
$48,717
Companies
31
Transactions
983
Medicare Patients
2,287
Medicare Billing
$271,562
Payment Breakdown by Category
Other$279,648 (77.5%)
Consulting$30,253 (8.4%)
Travel$29,560 (8.2%)
Food & Beverage$21,564 (6.0%)
Education$14.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $241,788 | 107 | 67.0% |
| Consulting Fee | $30,253 | 12 | 8.4% |
| Travel and Lodging | $29,560 | 133 | 8.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $26,400 | 11 | 7.3% |
| Food and Beverage | $21,564 | 703 | 6.0% |
| Honoraria | $10,460 | 13 | 2.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,000 | 1 | 0.3% |
| Education | $14.99 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $132,377 | 348 | $0 (2024) |
| Gilead Sciences, Inc. | $119,154 | 193 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $40,364 | 52 | $0 (2024) |
| Madrigal Pharmaceuticals | $29,658 | 27 | $0 (2024) |
| Merck Sharp & Dohme LLC | $26,594 | 42 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,032 | 25 | $0 (2024) |
| Dova Pharmaceuticals | $3,225 | 2 | $0 (2019) |
| Valeant Pharmaceuticals North America LLC | $2,323 | 12 | $0 (2017) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,618 | 215 | $0 (2024) |
| Echosens North America, Inc. | $260.50 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,717 | 157 | Madrigal Pharmaceuticals ($29,658) |
| 2023 | $21,446 | 140 | Gilead Sciences, Inc. ($11,113) |
| 2022 | $25,206 | 128 | ABBVIE INC. ($12,959) |
| 2021 | $19,099 | 74 | Gilead Sciences, Inc. ($8,840) |
| 2020 | $15,771 | 29 | Gilead Sciences, Inc. ($8,777) |
| 2019 | $77,481 | 149 | AbbVie, Inc. ($34,448) |
| 2018 | $75,230 | 162 | AbbVie, Inc. ($39,606) |
| 2017 | $78,088 | 144 | Gilead Sciences Inc ($24,937) |
All Payment Transactions
983 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/19/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $733.82 | General |
| Category: LIVER DISEASE | ||||||
| 12/19/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $132.96 | General |
| Category: LIVER DISEASE | ||||||
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,410.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/13/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/10/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $1,302.11 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $139.28 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $2.87 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $6.34 | General |
| Category: Gastroenterology | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $1.50 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/22/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $5.10 | General |
| Category: LIVER DISEASE | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.12 | General |
| 11/14/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: GI | ||||||
| 11/07/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/07/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $113.50 | General |
| Category: LIVER DISEASE | ||||||
| 11/06/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,375.00 | General |
| Category: VIROLOGY | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $12.10 | General |
| Category: Gastroenterology | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $1.96 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 700 | 801 | $446,272 | $85,671 |
| 2022 | 11 | 670 | 793 | $382,499 | $77,519 |
| 2021 | 12 | 571 | 670 | $308,974 | $70,242 |
| 2020 | 11 | 346 | 404 | $173,005 | $38,130 |
Total Patients
2,287
Total Services
2,668
Medicare Billing
$271,562
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 160 | 238 | $89,473 | $18,650 | 20.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 149 | 149 | $70,525 | $14,367 | 20.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 35 | 35 | $37,023 | $8,608 | 23.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 27 | 27 | $52,102 | $8,554 | 16.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 58 | 58 | $40,405 | $8,321 | 20.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 27 | 27 | $45,570 | $7,507 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 65 | $34,370 | $7,191 | 20.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 51 | 51 | $42,736 | $6,246 | 14.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 57 | 57 | $32,949 | $5,519 | 16.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 64 | 77 | $847.00 | $638.40 | 75.4% |
| 82272 | Stool analysis for blood, by peroxidase activity | Office | 2023 | 17 | 17 | $272.00 | $70.55 | 25.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 121 | 198 | $75,120 | $16,469 | 21.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 151 | 151 | $72,051 | $14,979 | 20.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 66 | 66 | $46,571 | $9,024 | 19.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 35 | 35 | $38,131 | $8,858 | 23.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 52 | 67 | $35,612 | $7,693 | 21.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 59 | 59 | $50,709 | $7,653 | 15.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 67 | 69 | $40,683 | $6,819 | 16.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 24 | 24 | $13,630 | $3,110 | 22.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 11 | 11 | $8,646 | $2,554 | 29.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 63 | 92 | $1,012 | $272.13 | 26.9% |
| 82272 | Stool analysis for blood, by peroxidase activity | Office | 2022 | 21 | 21 | $336.00 | $87.59 | 26.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 88 | 123 | $44,440 | $10,780 | 24.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 56 | 86 | $43,726 | $10,680 | 24.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 61 | 61 | $41,088 | $9,506 | 23.1% |
About Dr. Ari Bunim, MD
Dr. Ari Bunim, MD is a Internal Medicine healthcare provider based in Flushing, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386707933.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ari Bunim, MD has received a total of $361,039 in payments from pharmaceutical and medical device companies, with $48,717 received in 2024. These payments were reported across 983 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($241,788).
As a Medicare-enrolled provider, Bunim has provided services to 2,287 Medicare beneficiaries, totaling 2,668 services with total Medicare billing of $271,562. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Gastroenterology
- Location Flushing, NY
- Active Since 12/18/2006
- Last Updated 03/08/2017
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1386707933
Products in Payments
- Mavyret (Drug) $87,260
- Epclusa (Drug) $86,931
- OCALIVA (Drug) $34,552
- MAVYRET (Drug) $31,364
- REZDIFFRA (Drug) $29,574
- ZEPATIER (Drug) $26,393
- Vemlidy (Drug) $10,862
- OCA (Drug) $5,812
- Viekira (Drug) $5,666
- Vosevi (Drug) $4,878
- ENTYVIO (Biological) $3,950
- XIFAXAN (Drug) $3,509
- Doptelet (Drug) $3,225
- RINVOQ (Biological) $541.18
- SKYRIZI (Biological) $449.36
- Humira (Biological) $445.53
- HUMIRA (Biological) $350.25
- ZEPOSIA (Drug) $248.59
- TRULANCE (Drug) $227.97
- IBSRELA (Drug) $224.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Flushing
Calvin Pan, M.d, M.D
Internal Medicine — Payments: $975,186
Internal Medicine $975,186
Glenn Turett, M.d, M.D
Internal Medicine — Payments: $231,558
Internal Medicine $231,558
Weining Liang, Md, MD
Internal Medicine — Payments: $180,077
Internal Medicine $180,077
Dr. Yong Yu, M.d, M.D
Internal Medicine — Payments: $144,144
Internal Medicine $144,144
Dr. John Sciales, M.d, M.D
Internal Medicine — Payments: $92,715
Internal Medicine $92,715
Dr. Pauline Lau, Md, MD
Internal Medicine — Payments: $88,898
Internal Medicine $88,898